-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Akumin (AKU) Versus Its Rivals Financial Survey
Akumin (AKU) Versus Its Rivals Financial Survey
Akumin (NASDAQ:AKU – Get Rating) is one of 46 publicly-traded companies in the "Medical laboratories" industry, but how does it compare to its competitors? We will compare Akumin to related businesses based on the strength of its profitability, analyst recommendations, earnings, risk, valuation, institutional ownership and dividends.
Institutional and Insider Ownership
25.1% of Akumin shares are held by institutional investors. Comparatively, 53.5% of shares of all "Medical laboratories" companies are held by institutional investors. 17.0% of shares of all "Medical laboratories" companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Get Akumin alerts:Valuation and Earnings
This table compares Akumin and its competitors revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Akumin | $421.08 million | -$43.29 million | -1.60 |
Akumin Competitors | $1.04 billion | $57.33 million | -0.06 |
Volatility & Risk
Akumin has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Akumin's competitors have a beta of -1.65, meaning that their average share price is 265% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Akumin and its competitors, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Akumin | 2 | 0 | 0 | 0 | 1.00 |
Akumin Competitors | 136 | 719 | 1614 | 30 | 2.62 |
Akumin currently has a consensus target price of $0.63, indicating a potential downside of 63.45%. As a group, "Medical laboratories" companies have a potential upside of 100.90%. Given Akumin's competitors stronger consensus rating and higher probable upside, analysts clearly believe Akumin has less favorable growth aspects than its competitors.
Profitability
This table compares Akumin and its competitors' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Akumin | -14.16% | -29.00% | -3.87% |
Akumin Competitors | -1,501.07% | -52.65% | -22.32% |
Summary
Akumin competitors beat Akumin on 9 of the 13 factors compared.
Akumin Company Profile
(Get Rating)
Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.
Receive News & Ratings for Akumin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akumin and related companies with MarketBeat.com's FREE daily email newsletter.
Akumin (NASDAQ:AKU – Get Rating) is one of 46 publicly-traded companies in the "Medical laboratories" industry, but how does it compare to its competitors? We will compare Akumin to related businesses based on the strength of its profitability, analyst recommendations, earnings, risk, valuation, institutional ownership and dividends.
爱库明(纳斯达克:AKU-GET评级)是46家上市公司之一,但与竞争对手相比如何?我们将根据Akumin的盈利能力、分析师建议、收益、风险、估值、机构所有权和股息将Akumin与相关业务进行比较。
Institutional and Insider Ownership
机构和内部人持股
25.1% of Akumin shares are held by institutional investors. Comparatively, 53.5% of shares of all "Medical laboratories" companies are held by institutional investors. 17.0% of shares of all "Medical laboratories" companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
25.1%的Akumin股份由机构投资者持有。相比之下,所有“医学实验室”公司53.5%的股份由机构投资者持有。所有“医学实验室”公司17.0%的股份由内部人持有。强大的机构持股表明,大型基金管理公司、捐赠基金和对冲基金相信,一只股票的长期表现将好于大盘。
Valuation and Earnings
估值和收益
This table compares Akumin and its competitors revenue, earnings per share (EPS) and valuation.
该表比较了Akumin及其竞争对手的收入、每股收益(EPS)和估值。
Gross Revenue | Net Income | Price/Earnings Ratio | |
Akumin | $421.08 million | -$43.29 million | -1.60 |
Akumin Competitors | $1.04 billion | $57.33 million | -0.06 |
总收入 | 净收入 | 市盈率 | |
阿库明 | 4.2108亿美元 | -4,329万元 | -1.60 |
Akumin竞争对手 | 10.4亿美元 | 5733万美元 | -0.06 |
Volatility & Risk
波动性与风险
Akumin has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Akumin's competitors have a beta of -1.65, meaning that their average share price is 265% less volatile than the S&P 500.
Akumin的贝塔系数为0.04,这意味着其股价的波动性比S标准普尔500指数低96%。相比之下,Akumin的竞争对手的贝塔系数为-1.65,这意味着它们的平均股价波动性比S指数低265%。
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings for Akumin and its competitors, as reported by MarketBeat.
这是MarketBeat报道的Akumin及其竞争对手最近的评级细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Akumin | 2 | 0 | 0 | 0 | 1.00 |
Akumin Competitors | 136 | 719 | 1614 | 30 | 2.62 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
阿库明 | 2. | 0 | 0 | 0 | 1.00 |
Akumin竞争对手 | 136 | 719 | 1614 | 30个 | 2.62 |
Akumin currently has a consensus target price of $0.63, indicating a potential downside of 63.45%. As a group, "Medical laboratories" companies have a potential upside of 100.90%. Given Akumin's competitors stronger consensus rating and higher probable upside, analysts clearly believe Akumin has less favorable growth aspects than its competitors.
Akumin目前的共识目标价为0.63美元,表明潜在下行幅度为63.45%。作为一个整体,“医学实验室”公司有100.90%的潜在上行空间。鉴于Akumin的竞争对手更强的共识评级和更高的可能上行空间,分析师显然认为Akumin在增长方面不如竞争对手。
Profitability
盈利能力
This table compares Akumin and its competitors' net margins, return on equity and return on assets.
此表比较了Akumin及其竞争对手的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Akumin | -14.16% | -29.00% | -3.87% |
Akumin Competitors | -1,501.07% | -52.65% | -22.32% |
净利润率 | 股本回报率 | 资产回报率 | |
阿库明 | -14.16% | -29.00% | -3.87% |
Akumin竞争对手 | -1,501.07% | -52.65% | -22.32% |
Summary
摘要
Akumin competitors beat Akumin on 9 of the 13 factors compared.
在比较的13个因素中,Akumin的竞争对手在9个方面击败了Akumin。
Akumin Company Profile
Akumin公司简介
(Get Rating)
(获取评级)
Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.
Akumin Inc.在美国提供门诊诊断成像服务。它分为两个部分,放射学和肿瘤学。该公司提供各种医疗成像服务,包括磁共振成像,计算机断层扫描,正电子发射断层扫描,核医学,乳房X光检查,超声波,数字X线摄影,荧光透视,以及其他诊断或介入放射学程序通过网络约200拥有和/或经营的成像位置。它为46个州的约1,000家医院和卫生系统提供门诊放射学和肿瘤学服务和解决方案。Akumin Inc.成立于2015年,总部位于佛罗里达州种植园。
Receive News & Ratings for Akumin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akumin and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Akumin Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Akumin和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧